Biologically active insulin derivatives
The problem of hindered stability and affinity of existing insulin analogs is solved by introducing additional covalent linkages between the A and B chains, improving its biological activity and therapeutic effect.
Patent Information
- Application Number
- CN202410997092.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2013-12-05
- Filing Date
- 2014-12-04
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing insulin analogs are blocked when binding to insulin receptors, resulting in reduced affinity and insufficient stability and solubility, affecting their therapeutic effect.
By introducing additional covalent linkages between the insulin A and B chains, additional bonds are formed using amino acid side chain functional groups, reducing chain flexibility and improving chemical stability while retaining bonds between chains to reduce receptor affinity hinderance. The problem.
It improves the chemical stability and enzyme stability of insulin analogues, enhances its biological activity and therapeutic properties, and provides more effective blood sugar control.
Smart Images

Figure BDA0004960539450000011 
Figure BDA0004960539450000012 
Figure BDA0004960539450000081
Abstract
Description
[0001] This patent application is a divisional application of the patent application with application number 2014800663385, application date December 4, 2014, and invention name “Biologically active insulin derivatives”. Technical Field
[0002] The present invention relates to insulin analogs having therapeutic use in the treatment of diabetes. More particularly, but not exclusively, the present invention relates to single-chain insulin analogs containing an insulin A chain and a B chain, wherein the chains are linked together by functional groups of the amino acid side chains of the amino acids in the A chain or the B chain in addition to intermolecular disulfide bonds. Background Art
[0003] Insulin is a peptide hormone secreted by pancreatic beta cells that consists of two peptide chains (A and B) linked together by an intermolecular disulfide bond. The A chain also contains an additional intramolecular disulfide bond. Human insulin has structure 2.
[0004]
[0005] Insulin is obtained from the single-chain precursor preproinsulin, which consists of a propeptide of 24 amino acids followed by proinsulin containing 86 amino acids. The sequence of the propeptide is propeptide-[B chain]-Arg-Arg-[connecting peptide]-Lys-Arg-[A chain], where the connecting peptide consists of 31 amino acids. After enzymatic removal of the propeptide, three disulfide bonds are formed and proinsulin is produced.
[0006]
[0007] The mature insulin is then released by enzymatic cleavage at the Arg-Arg and Lys-Arg sites of the linker peptide.
[0008] The affinity of proinsulin for the insulin receptor is 100-fold lower than that of native insulin due to the hindrance of the residues necessary for receptor binding (ie, the N-terminal amino function of the A chain and the C-terminal carboxyl function of the B chain).
[0009] In the case of insulin therapy, the stability and solubility of insulin are very important.Many insulin analogs are known in the art.
[0010] For example, EP 1193272 discloses single-chain insulin analogs having insulin activity. These single-chain insulins have C-peptides with modified amino acids at positions 5 to 18 and are reported to have up to 42% of insulin activity.
[0011] US 5,597,796 discloses an insulin analog in which two or more amino acid residues are replaced by Glu and / or Asp. Similarly, US20090069216 and WO 2007 / 096332 disclose fast-acting single-chain insulins containing modified B chains and connecting peptides. The resulting analogs are particularly suitable for transdermal administration. US 8,192,957 discloses anti-fibrillation insulin and insulin analogs. US2010 / 0216690 discloses pegylated single-chain insulins, while WO 2007 / 104738 discloses acylated single-chain insulins.
[0012] WO 2005 / 054291 discloses a single-chain insulin analog, wherein the A chain and the B chain are connected by a connecting peptide of 5 to 11 amino acids. Similarly, WO 95 / 16708 also discloses a single-chain insulin analog, wherein the A chain and the B chain are connected by a connecting peptide of 1 to 15 amino acids, wherein the C-terminal amino acid residue is an amino acid other than Lys or Arg. EP0427296 discloses a single-chain insulin analog of the general formula B(1-29)-X n -YA(1-21) represented by human insulin precursor, wherein X n is a peptide chain having n naturally occurring amino acid residues. Similarly, EP0741188 discloses single-chain insulin derivatives represented by the formula b-BP-a, which have significant insulin activity; it is reported that these single-chain insulins have insulin activity and also have high affinity for IGF-1 receptors.
[0013] Insulin derivatives containing D-amino acids at the A1 position have been shown to retain their biological activity [Geiger R, Geisen K, Regitz G, Summ HD, Langner D., Hoppe Seylers Z Physiol Chem. 1980 Apr; 361(4): 563-70]. Insulin derivatives containing D-Glu at the B21 position have been shown to be equivalent to natural insulin [Wang SH, Hu SQ, Burke GT, Katsoyannis PG. J Protein Chem. 1991 Jun; 10(3): 313-24].
[0014] The present invention aims to provide novel single chain insulin analogs showing beneficial therapeutic properties, wherein two insulin chains are linked together via the amino acid side chain of at least one amino acid in the insulin A chain or B chain. Summary of the invention
[0015] One aspect of the present invention relates to a single-chain insulin analog comprising:
[0016] (A) the A chain of human or animal insulin, or their analogs or derivatives;
[0017] (B) the B chain of human or animal insulin, or an analog or derivative thereof;
[0018] (C) one or more disulfide bonds between the A chain and the B chain; and
[0019] (D) another covalent linkage L between a functional group of an amino acid of the A chain and a functional group of an amino acid of the B chain, at least one of the functional groups being an amino acid side chain functional group.
[0020] The insulin analogs claimed in the present invention differ from those known in the art in that the two insulin chains are linked via a functional group of at least one side chain of an amino acid that already forms part of the insulin A chain or B chain. Therefore, they differ from conventional single-chain peptides and cannot be considered as "proinsulin-like" peptides.
[0021] Many proinsulin-like peptides have been described in the literature and they are known in nature, which include conventional connecting peptides, for example those in which the N-terminal amino acid of one of the insulin chains is connected to the C-terminal amino acid of another chain. Such peptides can be made by conventional recombinant DNA techniques. However, it is impossible to prepare the insulin claimed in the present invention by recombinant DNA methods or other biological methods. Therefore, the insulin described in the present invention is a prototype of a new single-chain group of insulin not known before in this area.
[0022] The introduction of bonds between the functional groups of the amino acids of one chain and the side chain functional groups of the amino acids of the other chain means that at least one of the groups essential for biological activity (i.e. the N-terminal amino function of the A chain or the C-terminal carboxyl function of the B chain) is free.
[0023] Advantageously, the introduction of an additional bond between the A and B chains reduces chain flexibility, which in turn reduces fibrillation and precipitation, and improves chemical and enzymatic stability. Single-chain insulins in which the A and B chains are linked by a C-peptide generally show higher chemical stability, but tend to show lower affinity for the insulin receptor due to the hindrance of the N-terminal amino function of the A chain and the C-terminal carboxyl function of the B chain. The single-chain insulin analogs claimed in the present invention retain the advantages of having additional bonds between the chains to reduce flexibility, while also alleviating the problem of low affinity by releasing at most one or two terminal groups necessary for activity. DETAILED DESCRIPTION OF THE INVENTION
[0025] The single chain insulin analogs described in the present invention include a group of structurally related proteins in which the A chain and the B chain are covalently linked together via at least one side chain functional group of an amino acid contained in the A chain or the B chain.
[0026] Therefore, in a preferred embodiment, the present invention relates to a single-chain insulin analog, which includes the A chain or B chain of human or animal insulin or its analog, wherein the A chain or B chain is connected together by additional bonds formed between the functional groups of the amino acids of the A chain and the functional groups of the amino acids of the B chain in addition to the intermolecular disulfide bonds, wherein at least one of these functional groups is located on the amino acid side chain.
[0027] As used herein, the term "insulin analog" refers to a variant of insulin that is different from any naturally occurring insulin but can still perform similar actions as human insulin in the body in terms of blood sugar control. Through genetic engineering of the underlying DNA, the amino acid sequence of insulin can be altered, thereby changing its absorption, distribution, metabolism, and secretion characteristics. Although they are more commonly referred to as insulin analogs, the U.S. Food and Drug Administration (FDA) officially refers to these as "ligands for the insulin receptor." Improvements include insulin analogs that are more easily absorbed by the injection site and therefore act faster than subcutaneously injected natural insulin, and are intended to supply the drug levels of insulin needed at mealtimes (prandial insulin);
[0028] Those that are released slowly, between 8 and 24 hours, are designed to provide a base level of insulin (basal insulin) during the day and especially at night. Rapid-acting insulin analogs include insulin lispro (Eli Lilly) and insulin aspart (Novo Nordisk), while long-acting insulin analogs include NPH insulin, insulin glulisine (Sanofi-Aventis), insulin detemir (Novo Nordisk), and insulin glargine (Sanofi-Aventis).
[0029] Insulin analogs include variants of insulin. As used herein, the term "variant"
[0030] Any variant is included, wherein (a) one or more amino acid residues are replaced by a naturally occurring or non-natural amino acid residue; (b) the order of two or more amino acid residues is reversed; (c) (a) and (b) are present at the same time; (d) there is a spacer group between any two amino acid residues; (e) one or more amino acid residues are in a peptoid form; (f) the (NCC) backbone of one or more amino acid residues of the peptide is modified, or any combination of (a) to (f). Preferably, the variant is one of (a), (b) or (c).
[0031] More preferably, one or two amino acid residues are replaced by one or more other amino acid residues. Still more preferably, one amino acid residue is replaced by another amino acid residue. Preferably, the replacement is homologous.
[0032] Homologous substitutions (as used herein, substitution and replacement refer to the interchange of an existing amino acid residue with an alternative residue) may occur, i.e., homologous substitutions, such as substitution of a basic residue for a basic residue, an acidic residue for an acidic residue, a polar residue for a polar residue, etc. Non-homologous substitutions may also occur, i.e., substitution of one residue for another, or alternatively including non-natural amino acids, such as ornithine, diaminobutyric acid ornithine, norleucine ornithine, pyridylalanine, thienylalanine, naphthylalanine, and phenylglycine, a more detailed list of which is listed below. More than one amino acid residue may be modified at the same time.
[0033] As used herein, amino acids are classified according to the following categories:
[0034] Alkalinity: H, K, R;
[0035] Acidity: D, E;
[0036] Non-polar: A, F, G, I, L, M, P, V, W;
[0037] Polarity: C, N, Q, S, T, Y.
[0038] (using the internationally accepted single-letter amino acid symbols), and these categories are used to define homologous and nonhomologous substitutions. Thus, homologous substitution is used to refer to substitutions within the same category, while nonhomologous substitution is used to refer to substitutions by different categories or by non-natural amino acids.
[0039] In addition to amino acid spacers (such as glycine or β-alanine residues), suitable spacers that can be inserted between any two amino acid residues of the carrier portion include: alkyl groups, such as methyl, ethyl or propyl. Those skilled in the art will appreciate that another variant form, type (e), includes one or more amino acid residues in a peptoid form. For the avoidance of doubt, "peptoid form" is used herein to represent a variant amino acid residue in which the α-C substituent is located on the N atom of the residue rather than on the α-C. The preparation of peptides in peptoid form is known in the art, for example Simon RJ et al., PNAS (1992) 89 (20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13 (4), 132-134. Type (f) modification can be carried out by the method described in International Publication PCT / GB99 / 01855.
[0040] Amino acid variants (preferably type (a) or (b)) preferably occur independently at any position. As mentioned above, more than one homologous or non-homologous substitution may occur simultaneously. Other variants may be obtained by reversing the sequence of some amino acid residues within the sequence.
[0041] In one embodiment, the replacing amino acid residue is selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
[0042] Substituting amino acid residues may additionally be selected from unnatural amino acids as described below.
[0043] As used herein, the term "derivative" refers to insulins that are chemically modified, for example, at the N-terminal and / or C-terminal amino acid side chains. Preferably, the chemical modification is used to change the absorption, distribution, metabolism and secretion characteristics of the analog. Based on the chemical modification of animal insulin, semi-synthetic insulins have been used clinically for some time, such as NovoNordisk's enzymatic conversion of porcine insulin into semi-synthetic "human" insulin by removing single amino acids that are different from human diversity and chemically adding human amino acids.
[0044] In a preferred embodiment, insulin is chemically modified to change its isoelectric point. Normal unmodified insulin is soluble at physiological pH. Modified derivatives of insulin with isoelectric point shift have been obtained, so that they exist in the form of solubility equilibrium, wherein most of them precipitate but slowly dissolve in the blood and are eventually discharged by the kidneys.
[0045] In a preferred embodiment, the single chain insulin analogs of the present invention are derived from animal insulin.
[0046] The amino acid sequence of animal insulin in different mammals is similar to human insulin (human insulin INN). However, there is considerable activity in vertebrate species. Porcine insulin differs from human diversity by only one amino acid, and bovine insulin differs by only three amino acids. Both have approximately the same intensity of activity on human receptors. When human insulin (human insulin rDNA) could not be biosynthesized, bovine insulin and porcine insulin were the first insulin analogs used clinically (naturally occurring, obtained by extraction from animal pancreas). Insulin from sharks and some fish may also be effective.
[0047] Preferably, the single chain insulin analog of the present invention comprises the A chain of animal insulin, or an analog or derivative thereof.
[0048] Preferably, the single chain insulin analog of the present invention comprises the B chain of animal insulin, or an analog or derivative thereof.
[0049] In another preferred embodiment, the single-chain insulin analog of the present invention is derived from human insulin or an analog thereof. More preferably, the insulin is biosynthetic insulin (human insulin rDNA).
[0050] Preferably, the single chain insulin analog of the present invention comprises the A chain of human insulin, or an analog or derivative thereof.
[0051] Preferably, the single chain insulin analog of the present invention comprises the B chain of human insulin, or an analog or derivative thereof.
[0052] In a preferred embodiment, the covalent link L is located between the functional group of the A chain amino acids and the side chain functional group of the B chain amino acids.
[0053] As used herein, the term "functional group" refers to a specific group of atoms or bonds in a molecule that are responsible for the characteristic chemical reaction of that molecule.
[0054] In another preferred embodiment, the covalent linker L is located between the side chain functional group of the A chain amino acids and the side chain functional group of the B chain amino acids.
[0055] In a preferred embodiment, the covalent linkage L is located between the C-terminal amino acid of the A chain and the side chain functional group of the amino acid of the B chain.
[0056] In a preferred embodiment, the covalent linkage L is a direct bond.
[0057] In a preferred embodiment, the covalent link L is a direct bond between the side chain of the aspartic acid residue or glutamic acid residue of the C-terminal amino acid of the A chain and the side chain amino function of the lysine residue of the B chain.
[0058] In a preferred embodiment, the two insulin chains are directly connected by the functional groups of the amino acids that form the corresponding insulin chains. For example, in a particularly preferred embodiment, the A chain and the B chain are connected together by such a connection, which in the simplest case is a connection generated between the functional group of at least one amino acid side chain of one of the insulin chains and the terminal amino acid of the other insulin chain. For example, in a preferred embodiment, the connection is directly formed between the C-terminal amino acid of the A chain and the amino acid side chain of the B chain.
[0059] In a highly preferred embodiment, the two chains are linked directly between the side chain of an aspartic acid residue or a glutamic acid residue of the C-terminal amino acid of the insulin A chain and the side chain amino function of a lysine residue of the insulin B chain.
[0060] In another embodiment of the invention, two insulin chains are linked via a group L, which group L may comprise independent moieties X, Y, Z. For a particular embodiment, the groups X, Y, Z do not form part of the native A chain or B chain of insulin.
[0061] In a preferred embodiment, group L may comprise one or more natural or non-natural amino acids, peptides (which may comprise non-natural amino acid residues), or various peptide modifiers (such as diacids, diamines, polyethylene glycols and oligoethylene glycols, thiodiacids, thioamino acids, aminothiols, etc.). The order of components X, Y, Z may be interchangeable and optionally repeated.
[0062] More specifically, the linker group L contains at least one "modifier" in the form of a group X or a group Y. In addition, the linker group L may also comprise one or more conventional amino acid / peptide residues (Z).
[0063] As used herein, the term "modifier" refers to any group that is capable of changing the biological and physicochemical properties of a peptide.
[0064] In a particularly preferred embodiment, the covalent linker L is a group comprising:
[0065] (i) at least one group X; and / or
[0066] (ii) at least one group Y; and / or
[0067] (iii) at least one group Z;
[0068] in:
[0069] X is a group represented by formula 1a or 1b
[0070]
[0071] wherein d and e are each independently an integer selected from 0 to 10, and * and ** represent the point of attachment to the respective adjacent groups;
[0072] Y is a group selected from the following:
[0073]
[0074]
[0075] Where * and ** represent the points of attachment to the respective adjacent groups;
[0076] k, l, m, n, o, p, q, r and s are each independently an integer selected from 0 to 18; and
[0077] E is absent or selected from CH2, O, S and NR, wherein R is H, alkyl or aralkyl; and
[0078] Z is a natural or unnatural amino acid.
[0079] As used herein, the term "alkyl" includes saturated straight-chain and branched alkyl groups which may be (single or multiple) substituted or unsubstituted. Preferably, the alkyl group is C 1-20 Alkyl, more preferably C 1-15 Alkyl, more preferably C 1-12 Alkyl, more preferably C 1-6 Alkyl, more preferably C 1-3 Alkyl. Particularly preferred alkyl groups include, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl and hexyl. Suitable substituents include, for example, one or more groups selected from OH, O-alkyl, halogen, NH2, NH-alkyl, N-(alkyl)2, CF3, NO2, CN, COO-alkyl, COOH, CONH2, CO-NH-alkyl, CO-N(alkyl)2, SO2-alkyl, SO2NH2 and SO2-NH-alkyl groups.
[0080] As used herein, the term "aryl" refers to a C 6-12 Aromatic groups. Typical examples include phenyl and naphthyl, etc. Suitable substituents include, for example, one or more groups selected from OH, O-alkyl, halogen, NH2, NH-alkyl, N-(alkyl)2, CF3, NO2, CN, COO-alkyl, COOH, CONH2, CO-NH-alkyl, CO-N(alkyl)2, SO2-alkyl, SO2NH2 and SO2-NH-alkyl groups.
[0081] The term "aralkyl" is used as a combination of the above terms alkyl and aryl.
[0082] Natural amino acids include: alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
[0083] As used herein, the term "unnatural amino acid" includes α and α-disubstituted amino acids of natural amino acids, N-alkyl amino acids, lactic acid, halide derivatives such as trifluorotyrosine, p-chloro-phenylalanine, p-fluoro-phenylalanine, p-bromo-phenylalanine, p-NO2-phenylalanine, phenylglycine, sarcosine, penicillamine, D-2-methyltryptophan, phosphoserine, phosphothreonine, phosphotyrosine, pI-phenylalanine, L-allyl-glycine, β-alanine, β-aspartic acid, β-cyclohexylalanine, citrulline, homoserine, homocysteine, pyroglutamic acid, L-α-aminobutyric acid, L-γ-aminobutyric acid, L-α-aminoisobutyric acid, α-cyclohexylglycine, diaminobutyric acid, diaminopimelic acid, N-ε-dinitrophenyl-lysine, L-1-naphthylalanine, L-2-naphthylalanine, 3-(2-pyridinium)pyrrolidone, 3-(4-pyridyl)-L-alanine, 3-(3-pyridyl)-L-alanine, 3-(4-pyridyl)-L-alanine, N-ε-methyl-lysine, N,N-ε-dimethyl-lysine, N,N,N-ε-trimethyl-lysine, 3-mercaptopropionic acid, L-ε-aminocaproic acid, 7-aminoheptanoic acid, 6-aminocaproic acid, L-methionine sulfone, ornithine, L-norleucine, L-norvaline, p-nitro-L-phenylalanine amino acid, L-hydroxyproline, γ-glutamic acid, γ-aminobutyric acid, L-mercaptoproline, methyl derivatives of phenylalanine (Phe) (such as 4-methyl-Phe, pentamethyl-Phe, L-Phe(4-amino), L-Tyr(methyl), L-Phe(4-isopropyl), L-Tic(1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid), L-diaminopropionic acid and L-Phe(4-benzyl).
[0084] Advantageously, the introduction of unnatural amino acids results in increased enzymatic stability of the peptide.
[0085] The insulin analogs of the present invention may contain L- or D-forms of amino acids, i.e. one or more residues, preferably all residues may be L- or D-forms. In a preferred embodiment, the connection between the chains is between the C-terminal amino acid of the A chain of human or animal insulin, or their analogs or derivatives, and the side chain of the 29th lysine residue of the B chain of the human or animal insulin, or their analogs or derivatives.
[0086] In a preferred embodiment, the linker group L is between the side chain carboxyl group of the amino diacid present in the C-terminal portion of the A chain and the side chain of the diamino acid at position B29 (preferably but not exclusively) in the B chain (see Structure 3). As used herein, the term "C-terminal portion" refers to the last 10 amino acids of the A chain, including possible peptide extensions.
[0087]
[0088] Structure 3 = Side chain linkage on single-chain insulin
[0089] The linker can be of any length, as long as the linker gives the single-chain insulin analog the necessary structural configuration to enable it to have the functions of taking up glucose and binding to the insulin receptor.
[0090] It is particularly preferred to introduce the linker group L at the side chain of lysine (B29). In a highly preferred embodiment, the linker comprises a lipophilic modifier, or a modifier that combines lipophilicity and hydrophilicity.
[0091] In a preferred embodiment, the A chain comprises 1 to 21 amino acids of human insulin starting from the N-terminus of the A chain.
[0092] In a preferred embodiment, the A chain consists of 1 to 21 amino acids of human insulin starting from the N-terminus of the A chain.
[0093] In another preferred embodiment, the A chain comprises 1 to 20 amino acids of human insulin starting from the N-terminus of the A chain.
[0094] In another preferred embodiment, the A chain consists of 1 to 20 amino acids of human insulin starting from the N-terminus of the A chain.
[0095] In a preferred embodiment, the B chain comprises 1 to 29 amino acids of human insulin starting from the N-terminus of the A chain.
[0096] In a preferred embodiment, the B chain consists of 1 to 29 amino acids of human insulin starting from the N-terminus of the A chain.
[0097] In a preferred embodiment, the insulin B chain also contains up to 20 additional natural or unnatural amino acids at the C-terminus. Preferably, the B chain also contains 1 to 10 or more preferably 1 to 5 additional natural or unnatural amino acids at the C-terminus. In a highly preferred embodiment, the B chain also contains 1, 2 or 3 additional natural or unnatural amino acids at the C-terminus. In an even more preferred embodiment, the B chain also contains 1, 2 or 3 additional natural amino acids at the C-terminus.
[0098] In a preferred embodiment, the single chain insulin analog comprises one or more of the following:
[0099] (i) an intermolecular disulfide bond between the cysteine at position 7 of the insulin A chain and the cysteine at position 7 of the insulin B chain;
[0100] (ii) an intermolecular disulfide bond between cysteine at position 20 of the insulin A chain and cysteine at position 19 of the insulin B chain;
[0101] (iii) an intermolecular disulfide bond between cysteine at position 6 and cysteine at position 11 of the insulin A chain.
[0102] In a preferred embodiment, the single chain insulin analog comprises one of (i), (ii) and (iii) above.
[0103] In another preferred embodiment, the single-chain insulin analog comprises two of the above (i), (ii) and (iii).
[0104] In another preferred embodiment, the single chain insulin analog comprises (i), (ii) and (iii) above.
[0105] In a preferred embodiment, the single chain insulin analog has formula (I):
[0106]
[0107] in:
[0108] L is as defined above;
[0109] Each Aaa is independently a natural or unnatural amino acid;
[0110] f is 0 to 20;
[0111] R is OH or NH2.
[0112] In a preferred embodiment, R is OH, f is 0, 1, 2 or 3, and each Aaa is independently a natural amino acid. More preferably, the natural amino acid is selected from Arg and Thr.
[0113] In a preferred embodiment, L is selected from the following groups:
[0114] (i)-(X) a -(Y) b -(Z) c -;
[0115] (ii)-(Y) b -(X) a -(Z) c -;
[0116] (iii)-(Y) b -(Z) c -(X) a -;
[0117] (iv)-(X) a -(Z) c -(Y) b -;
[0118] (v)-(Z) c -(X) a -(Y) b -;
[0119] (vi)-(Z) c -(Y) b -(X) a -;
[0120] wherein a, b and c are each independently an integer selected from 0 to 5.
[0121] In a preferred embodiment, a, b and c are each independently 0, 1 or 2.
[0122] In a preferred embodiment, L is -(X) a -(Y) b -(Z) c -, where a is 1, and b and c are both 0.
[0123] In another preferred embodiment, L is -(X) a -(Y) b -(Z) c -, where a and b are 1, and c is 0.
[0124] In another preferred embodiment, L is -(X) a -(Y) b -(Z) c -, where a is 1, b is 2, and c is 0.
[0125] In another preferred embodiment, L is -(X) a -(Y) b -(Z) c -, where a is 1, b is 0, and c is 2.
[0126] In another preferred embodiment, L is -(X) a -(Y) b -(Z) c -, where a is 0, b is 0, and c is 1 or 2.
[0127] In a preferred embodiment, L is a direct bond, ie, a, b and c are all zero.
[0128] In a preferred embodiment, X is a group represented by formula 1a as defined above.
[0129] In a preferred embodiment, Y is a group represented by Formula 6 as defined above.
[0130] In a preferred embodiment, Y is a group represented by formula 6a or 6b:
[0131]
[0132] where * and ** indicate the points of attachment to the respective adjacent groups.
[0133] In a preferred embodiment, Y is a group represented by Formula 18 as defined above.
[0134] In a preferred embodiment, Y is a group represented by formula 18a, wherein l is 1, 2, 3, 4 or 5:
[0135]
[0136] where * and ** indicate the points of attachment to the respective adjacent groups.
[0137] In a preferred embodiment, the single chain insulin analog is selected from the group consisting of:
[0138]
[0139] Pharmaceutical composition
[0140] One aspect of the present invention relates to a pharmaceutical composition comprising an insulin analog as described herein, mixed with a pharmaceutically acceptable excipient, diluent, or carrier, or a mixture thereof. Although the peptides of the present invention (including pharmaceutically acceptable salts, esters, and pharmaceutically acceptable solvates thereof) can be used alone, they are usually mixed with a pharmaceutical carrier, excipient, or diluent for administration, particularly for human treatment. The pharmaceutical composition can be used for human or animal use in human and veterinary medicine.
[0141] Examples of such suitable excipients for use in the various forms of the pharmaceutical compositions described herein may be found in "Handbook of Pharmaceutical Excipients, 2nd Edition, edited by A Wade and PJ Weller (1994).
[0142] Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (AR Gennaro edit. 1985).
[0143] Examples of suitable carriers include lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, etc. Suitable diluents include ethanol, glycerol and water.
[0144] The selection of pharmaceutical carrier, excipient or diluent can be selected according to the intended route of administration and standard pharmaceutical practice. The pharmaceutical composition may include any suitable binder, lubricant, suspending agent, coating agent, solubilizing agent as a carrier excipient or diluent, or may include any suitable binder, lubricant, suspending agent, coating agent, solubilizing agent in addition to a carrier, excipient or diluent.
[0145] Examples of suitable binders include starch, gelatin, natural sugars (such as glucose, anhydrous lactose, free lactose, beta-lactose, corn sweeteners), natural and synthetic guar gums (such as gum arabic, gum tragacanth or sodium alginate), carboxymethylcellulose and polyethylene glycol.
[0146] Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
[0147] Preservatives, stabilizers, dyes, and even flavoring agents may be added to the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid, and parabens. Antioxidants and suspending agents may also be used.
[0148] Salt / Ester
[0149] The insulin analogs of the present invention may exist in the form of salts or esters, particularly pharmaceutically acceptable salts or esters.
[0150] The pharmaceutically acceptable salts of the compounds of the present invention include suitable acid addition salts or base salts thereof. Suitable pharmaceutically acceptable salts can be found in the review by Berge et al., J Pharm Sci, 66, 1-19 (1977). Salts can be formed with strong inorganic acids, such as mineral acids (e.g., sulfuric acid, phosphoric acid or hydrohalic acid); with strong organic carboxylic acids, such as unsubstituted or substituted (e.g., substituted by halogen) alkanecarboxylic acids having 1 to 4 carbon atoms (e.g., acetic acid); with saturated or unsaturated dicarboxylic acids, such as oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid or terephthalic acid; with hydroxycarboxylic acids, such as ascorbic acid, glycolic acid, lactic acid, malic acid, tartaric acid or citric acid; with amino acids, such as aspartic acid or glutamic acid; with benzoic acid; or with organic sulfonic acids, such as unsubstituted or substituted (e.g., substituted by halogen) (C1-C4)-alkyl- or aryl-sulfonic acids (e.g., methanesulfonic acid or p-toluenesulfonic acid).
[0151] Depending on the functional group to be esterified, esters can be formed using organic acids or alcohols / hydroxides. Organic acids include carboxylic acids such as unsubstituted or substituted (e.g., halogen-substituted) alkanecarboxylic acids having 1 to 12 carbon atoms (e.g., acetic acid); saturated or unsaturated dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, phthalic acid or terephthalic acid; hydroxycarboxylic acids such as ascorbic acid, glycolic acid, lactic acid, malic acid, tartaric acid or citric acid; with amino acids such as aspartic acid or glutamic acid; phenolic acid; or with organic sulfonic acids such as unsubstituted or substituted (e.g., halogen-substituted) (C1-C4)-alkyl- or aryl-sulfonic acids (e.g., methanesulfonic acid or p-toluenesulfonic acid). Suitable hydroxides include inorganic hydroxides such as sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide. Alcohols include unsubstituted or substituted (e.g., halogen-substituted) alkanols having 1 to 12 carbon atoms.
[0152] Enantiomers / Tautomers
[0153] In all aspects of the invention described herein, the invention includes all suitable enantiomers and tautomers of the analogs of the invention. Those skilled in the art are able to recognize compounds with optical properties (one or more chiral carbon atoms) or tautomeric properties. The corresponding enantiomers and / or tautomers can be separated or prepared by methods known in the art.
[0154] Stereoisomers and geometric isomers
[0155] Some analogs of the invention may exist as stereoisomers and / or geometric isomers, for example, they may have one or more asymmetric and / or geometric centers, thereby existing in two or more stereoisomers and / or geometric forms. The invention includes the use of all independent stereoisomers and geometric isomers of these analogs and mixtures thereof. The terms used in the claims include these forms, provided that the form retains the appropriate functional group activity (although not necessarily to the same extent).
[0156] The present invention also includes all suitable isotopic variations of these analogs or their pharmaceutically acceptable salts. An isotopic variation is defined as the replacement of at least one atom by an atom having the same atomic number but having an atomic mass different from the atomic mass usually found in nature. Examples of isotopes that can be introduced into the agents and their pharmaceutically acceptable salts include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2 H. 3 H. 13 C. 14 C. 15 N. 17 O. 18 O. 31 P. 32 P. 35 S.18 F and 36 Cl. Specific isotopic variants are useful in studies of drug and / or substrate tissue distribution, e.g. 3 H or 14 The radioactive isotope of C. Due to its ease of preparation and detection, tritium labeling (i.e. 3 H) and C-14 (i.e. 14 C) isotopes are particularly preferred. In addition, deuterium (i.e. 2 H) may have certain therapeutic advantages due to higher metabolic stability, such as increasing the half-life in vivo or reducing the required dosage, and is therefore preferred in some cases. Isotopic variants of the analogs and pharmaceutically acceptable salts thereof described in the present invention can generally be prepared by conventional methods using suitable isotopic variants of appropriate reagents.
[0157] Solvate
[0158] The present invention also includes solvated forms of the analogs of the present invention. The terms used in the claims include these forms.
[0159] Polymorph
[0160] The present invention also relates to various crystalline forms, polymorphs and (anhydrous) hydrated forms of the analogs of the present invention. The pharmaceutical industry has established such a way that chemical compounds can be isolated in any such form by slightly changing the purification method and / or separation method of the solvent used in the synthetic preparation of the compound.
[0161] Prodrug
[0162] The present invention also includes analogs of the present invention in the form of prodrugs. Such prodrugs are generally analogs of the present invention in which one or more suitable groups are modified so that the modification can be reversed when administered in a human or mammalian subject. Although a second agent may also be administered with such a prodrug so as to effect the reversal in vivo, such reversal is generally effected by naturally occurring enzymes in the subject. Examples of such modifications include esters (e.g., any of those described above), wherein the reversal can be effected by esterases. Other such systems are well known to those skilled in the art.
[0163] Application
[0164] The pharmaceutical compositions of the present invention may be administered by oral, rectal, vaginal, parenteral, intramuscular, intraperitoneal, intraarterial, intrathecal, intrabronchial, subcutaneous, intradermal, intravenous, intranasal, buccal or sublingual routes.
[0165] For oral administration, particular uses are made into compressed tablets, pills, tablets, gellules, drops and capsules. Preferably, these compositions contain 1 mg to 250 mg of active ingredient in a unit dose, and more preferably contain 10 mg to 100 mg of active ingredient.
[0166] Other forms of use include solutions or emulsions that can be injected intravenously, intra-arterially, intrathecally, subcutaneously, intradermally, intraperitoneally or intramuscularly, and can be prepared from sterile solutions or sterilizable solutions. Pharmaceutical compositions of the present invention can also be in the form of suppositories, vaginal suppositories, suspensions, emulsions, lotions, ointments, creams, gels, sprays, solutions or powdered powders.
[0167] An alternative to transdermal administration is the use of a skin patch. For example, the active ingredient can be introduced into a cream (composed of an aqueous emulsion of polyethylene glycol or liquid paraffin). The active ingredient can also be introduced into an ointment composed of a white wax or white soft paraffin base and, as required, stabilizers and preservatives at a concentration of 1% to 10% by weight.
[0168] The injectable form may contain from 10 mg to 1000 mg of active ingredient in a unit dose, more preferably from 10 mg to 250 mg of active ingredient.
[0169] The composition may be formulated in unit dosage form, ie, in the form of discrete portions containing a unit dosage, or multiple units or subunits of a unit dosage.
[0170] dose
[0171] Without undue experimentation, those skilled in the art can easily determine the appropriate dosage of a prepared composition administered to a subject. Generally, the physician will be able to determine the actual dosage that best suits the individual patient, and this will depend on a series of factors: including the activity of the specific compound employed, the metabolic stability and duration of action of the compound, the subject's age, weight, health status, sex, diet, mode and time of administration, excretion rate, drug combination, severity of a particular condition, and treatment experienced by the individual. The dosages disclosed herein are exemplary average situations. These are of course individual situations, which may include higher or lower dosage ranges, and these are all included within the scope of the present invention.
[0172] Depending on the need, the agent is administered at a dosage of 0.01 mg / kg to 30 mg / kg body weight, such as 0.1 mg / kg to 10 mg / kg body weight, more preferably 0.1 mg / kg to 1 mg / kg body weight.
[0173] In an exemplary embodiment, one or more doses of 10 mg / day to 150 mg / day may be administered to the patient.
[0174] Therapeutic Uses
[0175] Another aspect of the invention relates to the use of a single chain insulin analogue as described above in medicine.
[0176] Another aspect of the invention relates to the use of a single chain insulin analogue as described above in the treatment or prevention of diabetes, or in the treatment or prevention of hyperglycemia.
[0177] Another aspect of the present invention relates to the use of the single-chain insulin analogue as described above in the preparation of a medicament for treating diabetes, or treating or preventing hyperglycemia.
[0178] As used herein, the phrase "preparation of a medicament" includes the use of an analog of the invention directly as a medicament in addition to its use in screening for further therapeutic agents or at any stage in the preparation of such a medicament.
[0179] Another aspect of the invention relates to a method for treating diabetes, or treating or preventing hyperglycemia in a subject in need thereof, said method comprising administering a therapeutically effective amount of a single chain insulin analogue as described above.
[0180] The present invention is further described below by way of non-limiting examples. DETAILED DESCRIPTION
[0181] Example
[0182] abbreviation
[0183] Boc tert-Butyloxycarbonyl
[0184] CTC Chlorotrityl chloride
[0185] NMP N-Methylpyrrolidone
[0186] DCM Dichloromethane
[0187] TFA Trifluoroacetic acid
[0188] RE Rotary Evaporator
[0189] DEE Diethyl ether
[0190] DIC N,N'-Diisopropylcarbodiimide
[0191] HOBt Hydroxybenzotriazole
[0192] HOSu N-Hydroxysuccinimide
[0193] DMF dimethylformamide
[0194] EDAC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
[0195] RT Room temperature
[0196] DTT Dithiothreitol
[0197] DMSO Dimethyl sulfoxide
[0198] MMt Monomethoxytrityl
[0199] Trt Trityl
[0200] DIPEA N,N-Diisopropylethylamine
[0201] Fmoc Fluorenylmethoxycarbonyl
[0202] MeOH Methanol
[0203] AcOH Acetic acid
[0204] TFE Trifluoroethanol
[0205] Dde N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl)
[0206] Example 1
[0207] Synthesis of single-chain insulin of structure 10
[0208] (A) Synthesis of partial protection of structure 6 and carboxyl-activated insulin Gly(A21) chain
[0209] 3.0 g (1.0 mmol) of H-Gly-O-CTC resin (commercially available, product of CBL-Patras) were extended to resin-bound protected Gly(A21) chains using Fmoc-amino acids (product of CBL-Patras) and DIC / HOBt for activation of amino acids other than Gly(A21) residues (which were introduced using Boc-Gly-OH). The resin was then washed 4 times with NMP and 6 times with DCM, and the protected peptide was then cleaved from the resin and oxidized by simultaneous washing 8 times with 1% TFA in DCM containing 20.0 mmol of iodine. The filtrate from the 1% TFA wash was dropped into a 3% Na2S2O3 solution, and the DCM layer was washed with the Na2S2O3 solution and water, concentrated in RE, and the protected peptide was then precipitated with the addition of DEE, washed with DEE and dried in vacuo to constant weight. Yield: 3.04 g (90.0%).
[0210]
[0211] (B) Structure 8 selectively binds to Lys 29Solid Phase Synthesis of Human Insulin B Chain with Deprotected B(Arg31) and B(Arg32)
[0212] 4.0 g (1.0 mmol) of H-Arg(Pbf)-O-CTC resin (purchased from CBL-Patras) was extended into resin-bound protected Arg(B31), Arg(B32) chains using Fmoc-amino acids and DIC / HOBt for activation of amino acids except Phe(B1) residues (which were introduced using Boc-Phe-OH). The resin was then washed 4 times with NMP, 6 times with DCM, and then 8 times with 1% TFA in DCM to cleave the protected peptide from the resin. The filtrate from the 1% TFA wash was dropped into a 1% aqueous pyridine solution, the DCM layer was washed with water, concentrated in RE, and then the protected peptide was precipitated with the addition of DEE, washed with DEE and dried in vacuo to constant weight. Yield: 5.61 g (90.2%).
[0213]
[0214] (C) Condensation-synthesis of single-chain insulin Nr.10 in solution
[0215] 0.12 (0.1 mmol) HOSu and 0.17 g (0.1 mmol) EDAC were added to a solution of 427.1 mg (0.1 mmol) protected A chain Nr.6 in 10.0 ml DMF, and the mixture was stirred at room temperature for 20 minutes. Then 621.9 mg (0.1 mmol) of insulin B chain Nr.8 selectively deprotected in the B chain was added, and the resulting mixture was stirred at room temperature for another 6 hours. The resulting solution was then dropped into 100 ml of ice water, the resulting solid was filtered, washed with water and dried in vacuo. The resulting solid was then dissolved in 30 ml of TFA / DTT / water (94:3:3) precooled at 0°C, and stirred for 1 hour, and the mixture was then warmed to room temperature and stirred at room temperature for another 3 hours. The mixture was then concentrated in vacuo to about 5 ml in RE and 100 ml of ice-cold DEE was added. The precipitated solid was filtered, washed with DEE and dried in vacuo to constant weight. The crude insulin was then dissolved in a solution of 20% DMSO in Na2HPO4 at pH 7.8 and stirred at room temperature for another 48 hours. The resulting solution was then acidified, loaded on a C18 Chromasil column and purified by HPLC. The fractions containing the main product were collected and lyophilized. Yield: 62.3 mg (10.7%) of net peptide.
[0216]
[0217] Example 2
[0218] Synthesis of single-chain insulin with structure 15
[0219] (A) Structure 11 is protected, carboxyl activated and Asp 21 Synthesis of oxidized insulin A chain
[0220] 4.0 g (1.0 mmol) of H-Asp (CTC resin) was reacted with Fmoc-amino acid (product of CBL-Patras) and DIC / HOBt for activating amino acids except for Gly (A1) residue (which was introduced using Boc-Gly-OH). t Bu (purchased from CBL-Patras) was extended into a protected Asp (A21) chain bound to the resin. The resin was then washed 4 times with NMP and 6 times with DCM, and then the protected peptide was cleaved from the resin and oxidized by washing 8 times with 1% TFA in DCM containing 20.0 mmol iodine. The filtrate from the 1% TFA wash was dropped into a 3% Na2S2O3 solution, and the DCM layer was washed with the Na2S2O3 solution and water, concentrated in RE, and then the protected peptide was precipitated with the addition of DEE, washed with DEE and dried in vacuo to constant weight. Yield: 2.97 g (87.5%).
[0221]
[0222] (B) Synthesis of des-Thr30 human insulin selectively deprotected at the Lys29 side chain of structure 12
[0223] 3.2 g (1.0 mmol) of H-Lys(MMT resin)-OTrt (obtained by reacting Fmoc-Lys-OH with MMt-chloride resin and DIPEA in DCM, followed by esterification of the resin-bound Fmoc-Lys-OH obtained from Trt-chloride) was extended to a resin-bound protected desThr(B30) human insulin B chain using Fmoc-amino acid (product of CBL-Patras) and DIC / HOBt for activation of amino acids other than Phe(B1) residues (which were introduced using Boc-Phe-OH). The resin was then washed 4 times with NMP, 6 times with DCM, and then 8 times with 1% TFA in DCM to cleave the protected peptide from the resin. The filtrate from the 1% TFA wash was dropped into a 1% aqueous pyridine solution, the DCM layer was washed with water, concentrated in RE, and then the protected peptide was precipitated with the addition of DEE, washed with DEE and dried in vacuo to constant weight. Yield: 4.93 g (94.1%).
[0224]
[0225] (C) Condensation of partially protected insulin A and B chains in solution
[0226] 0.12 (0.1 mmol) HOSu and 0.17 g (0.1 mmol) EDAC were added to a solution of 339.6 mg (0.1 mmol) protected A chain Nr.11 in 10.0 ml DMF, and the mixture was stirred at room temperature for 20 minutes. Then 524.5 mg (0.1 mmol) of insulin B chain Nr.12, which was selectively deprotected in the B chain, was added, and the resulting mixture was stirred at room temperature for another 6 hours. The resulting solution was then dropped into 100 ml of ice water, the resulting solid was filtered, washed with water and dried in vacuo. The resulting solid was then dissolved in 30 ml of TFA / DTT / water (94:3:3) precooled at 0°C, and stirred for 1 hour, and the mixture was then warmed to room temperature and stirred at room temperature for another 3 hours. The mixture was then concentrated in vacuo to about 5 ml in RE and 100 ml of ice-cold DEE was added. The precipitated solid was filtered, washed with DEE and dried in vacuo to constant weight. The crude insulin was then dissolved in a solution of 20% DMSO in Na2HPO4 at pH 7.8 and stirred at room temperature for another 48 hours. The resulting solution was then acidified, loaded on a C18 Chromasil column and purified by HPLC. The fractions containing the main product were collected and lyophilized. Yield: 78.9 mg (14.5%) of net peptide.
[0227]
[0228] Example 3
[0229] Synthesis of single-chain insulin with structure 19
[0230] (A) Synthesis of protected insulin A chain having structure 17
[0231] 4.13 g (10.0 mmol) of 6-Fmoc-amino (ethylthio) hexanoic acid (obtained by a protocol well known in the art using Fmoc-cysteamine and 6-bromohexanoic acid) was dissolved in 200 ml of DCM, then 20.0 g (1.6 mmol / g) of CTC-chlororesin and 7.75 g (60 mmol) of DIPEA were added and the resulting mixture was shacked for 2 hours at room temperature. 10.0 ml of MeOH was then added and the mixture was shacked again for 1 hour. The resin was filtered and washed 3 times with DCM / DIPEA / MeOH and 6 times with DCM. The resulting resin-bound amino acid chain was then extended with the sequential coupling of Fmoc-amino acids and activation of the resin-bound protected peptide 16 with DIC / HOBt. The resin 16 was then washed 4 times with NMP and 6 times with DCM, and the protected peptide was then cleaved from the resin and simultaneously oxidized by washing 8 times with 1% TFA in DCM containing 200.0 mmol of iodine. The filtrate from the 1% TFA wash was dropped into 1% aqueous pyridine, the DCM layer was washed with water, concentrated in RE, then the protected peptide precipitated with the addition of DEE, washed with DEE and dried in vacuo to constant weight. Yield: 34.7 g (90.8%).
[0232]
[0233] (B) Condensation of partially protected and modified insulin A of structure 17 with partially protected desThr(B30) insulin B chain of structure 12 in solution
[0234] 0.12 (0.1 mmol) HOSu and 0.17 g (0.1 mmol) EDAC were added to a solution of 382.3 mg (0.1 mmol) protected A chain Nr.17 in 10.0 ml DMF, and the mixture was stirred at room temperature for 20 minutes. Then 524.5 mg (0.1 mmol) of des (B30) insulin B chain Nr.12 selectively deprotected at the side chain of Lys (B29) was added, and the resulting mixture was stirred at room temperature for another 6 hours. The resulting solution was then dropped into 100 ml of ice water, the resulting solid was filtered, washed with water and dried in vacuo. The resulting solid was then dissolved in 30 ml of TFA / DTT / water (94:3:3) precooled at 0°C, and stirred for 1 hour, and then the mixture was warmed to room temperature and stirred at room temperature for another 3 hours. The mixture was then concentrated in vacuo to about 5 ml in RE and 100 ml of ice-cold DEE was added. The precipitated solid was filtered, washed with DEE and dried in vacuo to constant weight. The crude insulin was then dissolved in 20% DMSO in Na2HPO4 at pH 7.8 and stirred at room temperature for another 48 hours. The resulting solution was then acidified, loaded onto a C18 Chromasil column and purified by HPLC.
[0235] Fractions containing the major product were collected and lyophilized. Yield: 127.4 mg (22.8%) of net peptide.
[0236]
[0237]
[0238] Example 4
[0239] Synthesis of single-chain insulin of structure 23
[0240] Solid phase synthesis of single chain insulin Glu(A21), des Thr(B30), wherein the insulin chains are linked via the side chains of Glu(A21) and Lys(B29) and an oligoethylene glycol modifier.
[0241] The synthesis was started by solid phase synthesis of the B chain on 4-methyl-diphenylmethyl (diphenylmethyl) resin. After completion of the Lys (B29) side chain synthesis, the Mmt functional group was removed by treatment with DCM / TFE / AcOH (7:2:1) for 3 hours at room temperature, thereby providing a partially protected resin-bound peptide of structure 21. Two 2-(2-(2-aminoethoxy)ethoxy)acetic acid groups were then introduced on the Lys side chain using the corresponding Fmoc-derivative followed by coupling with Fmoc-Glu-OtBu. The remaining A chain was assembled on the Nα-functionality of Glu (A21) using Fmoc-amino acids. To form disulfide bonds, the resin-bound peptide was treated with 1% I2 in DCM / TFE (9:1) after completion of the synthesis. The resin was then washed with DCM and treated with TFA / DTT / H2O (94:3:3) at 0°C for 15 minutes and filtered. The resin was then washed three times with a TFA solution, and the combined filtrates were left at 0°C for another 3 hours. The resulting solution was concentrated in RE, and the remaining oil was dropped into ice-cold DEE. The precipitated material was filtered, washed with DEE and dried in vacuo. The crude insulin was then dissolved in a 20% DMSO solution of Na2HPO4 at pH 7.8 and stirred at room temperature for another 48 hours. The resulting solution was then acidified, loaded onto a C18 Chromasil column and purified by HPLC. The fractions containing the main product were collected and lyophilized. Yield: 82.4 mg (14.29%) of net peptide.
[0242]
[0243] Example 5
[0244] Synthesis of single-chain insulin of structure 24 on 2-chlorotrityl resin
[0245] Starting from 1.00 mmol H-Thr(tBu)-O-CTC resin, the synthesis was performed as described in Example 3, except that Fmoc-Lys(Dde)-OH was used instead of Fmoc-Lys(Mmt)-OH when introducing Lys(B29), and the selective removal of Dde was performed conventionally using 2%-hydrazine in NMP. Yield: 94.3 mg (15.4%).
[0246]
[0247] Various modifications and variations of the various aspects of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been described in conjunction with specific preferred embodiments, it should be understood that the present invention is not limited to these specific embodiments. In fact, various modifications of the modes of implementing the present invention that are apparent to those skilled in the relevant art should be included within the scope of the following claims.
Claims
1. A single-chain insulin analog, comprising: (A) the A chain of human or animal insulin, or their analogs or derivatives; (B) the B chain of human or animal insulin, or an analog or derivative thereof; (C) one or more disulfide bonds between the A chain and the B chain; and (D) another covalent linkage L between a functional group of an amino acid of the A chain and a functional group of an amino acid of the B chain, at least one of the functional groups being an amino acid side chain functional group.
2. The single-chain insulin analog according to claim 1, wherein the further covalent link L is located between a functional group of an amino acid of the A chain and a side chain functional group of an amino acid of the B chain.
3. The single-chain insulin analog according to claim 1 or 2, wherein the further covalent linker L is located between the C-terminal amino acid of the A chain and the side chain functional groups of the amino acids of the B chain.
4. The single chain insulin analog according to any one of the preceding claims, wherein the further covalent linkage L is a direct bond.
5. The single-chain insulin analog according to claim 4, wherein the further covalent link L is a direct bond between the side chain of the aspartic acid residue or glutamic acid residue of the C-terminal amino acid of the A chain and the side chain amino functionality of a lysine residue in the B chain.
6. The single chain insulin analog according to any one of claims 1 to 3, wherein the other covalent linker L is a group comprising: (i) at least one group X; and / or (ii) at least one group Y; and / or (iii) at least one group Z; in: X is a group represented by formula 1a or 1b wherein d and e are each independently an integer selected from 0 to 10, and * and ** represent the point of attachment to the respective adjacent groups; Y is a group selected from the following: Where * and ** represent the points of attachment to the respective adjacent groups; k, l, m, n, o, p, q, r and s are each independently an integer selected from 0 to 18; and E is absent or selected from CH2, O, S and NR, wherein R is H, alkyl or aralkyl; and Z is a natural or unnatural amino acid.
7. A single-chain insulin analog according to any one of the preceding claims, wherein L links the carboxyl terminal amino acid of the A chain of the human or animal insulin, or their analogs or derivatives, to the side chain of the lysine residue at position 29 of the B chain of the human or animal insulin, or their analogs or derivatives.
8. The single chain insulin analog according to any one of the preceding claims, wherein the A chain comprises 1 to 21 or 1 to 20 amino acids of human insulin starting from the N-terminus of the A chain.
9. The single chain insulin analog according to any one of the preceding claims, wherein the B chain comprises 1 to 29 amino acids of human insulin starting from the N-terminus of the A chain.
10. The single chain insulin analog according to claim 9, wherein the insulin B chain further comprises up to 20 additional natural or unnatural amino acids at the C-terminus.
Citation Information
Patent Citations
Single-chain insulin
CN102816228A
Single chain insulin agonists exhibiting high activity at the insulin receptor
CN103068842A
Single-chain insulin
CN1902226A
Process for the preparation of insulin derivatives cross-linked by a dicarboxylic acid group at the amino a-1 glycine and amino b-29 lysine
US3847893A
Insulin analogues with an acyl and alkylene glycol moiety
WO2009022005A1
